Show Notes
Busarello E et al., Nature Communications - This episode covers the Cell Marker Accordion, an integrated marker database plus R package and Shiny app that weights marker genes by specificity and evidence consistency to deliver faster, more accurate and interpretable cell-type annotations in single-cell and spatial datasets, including disease contexts. Key terms: single-cell, spatial-omics, cell-type annotation, marker-database, disease-biomarkers.
Study Highlights:
The authors built the Cell Marker Accordion by integrating 23 marker gene sources and standardizing nomenclature to the Cell Ontology and Uberon. Markers are weighted by specificity and an evidence consistency score to produce gene- and cell-type impact metrics used for annotation. Benchmarking across multiple human and murine single-cell and spatial datasets showed an average ~23% improvement in annotation accuracy versus other marker-based tools and much faster runtimes. The tool additionally identifies disease-critical cells, extracts altered marker signatures, and highlights pathway activation and cell-cycle changes.
Conclusion:
The Cell Marker Accordion is a fast, flexible, and interpretable platform that standardizes and improves annotation of single-cell and spatial omics in health and disease, enabling detection of disease-critical cells and candidate biomarkers.
Music:
Enjoy the music based on this article at the end of the episode.
Article title:
Cell Marker Accordion: interpretable single-cell and spatial omics annotation in healthand disease
First author:
Busarello E
Journal:
Nature Communications
DOI:
10.1038/s41467-025-60900-4
Reference:
Busarello E., Biancon G., Cimignolo I., et al. Cell Marker Accordion: interpretable single-cell and spatial omics annotation in healthand disease. Nature Communications (2025). DOI: 10.1038/s41467-025-60900-4
License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/
Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00
Official website https://basebybase.com
On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics.
Episode link: https://basebybase.com/episodes/cell-marker-accordion
QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-08-06.
QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited transcript segments describing the Cell Marker Accordion platform, marker weighting (SPS/ECs), use of positive/negative markers, benchmarking results (accuracy and speed), and disease-related findings (AML LHSCs, glioblastoma, MDS, METTL3 innate immunity). Cross-checked with canonical article.
- transcript topics: Marker database inconsistencies across reference sources; Cell Marker Accordion platform: integration and ontology standardization; Marker weighting: specificity score (SPS) and evidence consistency score (ECs); Positive and negative markers and their impact on annotation; Benchmark results: accuracy improvement and speed; Disease-focused applications and interpretable outputs
QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0
Metadata Audited:
- article_doi
- article_title
- article_journal
- license
Factual Items Audited:
- Integrates 23 marker databases and standardizes to Cell Ontology and Uberon
- Uses specificity score (SPS) and evidence consistency score (ECs) to weight markers
- Considers both positive and negative markers in annotation
- Benchmark shows ~23% average improvement in annotation accuracy across multiple datasets and very fast runtimes (~2 minutes)
- Identifies disease-critical cell types and pathways (e.g., AML LHSCs, neoplastic monocytes, glioblastoma, lung adenocarcinoma, MDS, METTL3-related innate immunity)
- Provides interpretable outputs detailing genes/pathways driving annotations
QC result: Pass.
